uBriGene and Cellinfinity BIO Partner to Advance In Vivo CAR-T Therapies

Strategic collaboration aims to lower costs and improve patient access to next-gen cancer treatments.

Mar. 30, 2026 at 1:43pm

Got story updates? Submit your updates here. ›

uBriGene Biosciences, a leading CDMO for advanced therapy medicinal products, has announced a strategic partnership with Cellinfinity BIO, a biotech company developing in vivo CAR-T therapies for hematologic and solid tumors. uBriGene will leverage its highly productive LVV Turbo™ lentiviral vector manufacturing platform to deliver efficient, cost-effective GMP production, process development, and regulatory support for Cellinfinity's CAR-T programs CIB-301 and CIB-350.

Why it matters

In vivo CAR-T therapies have the potential to significantly reduce treatment costs compared to traditional ex vivo approaches, improving patient accessibility. This partnership combines Cellinfinity's innovative CAR-T technologies with uBriGene's manufacturing expertise, accelerating the clinical advancement of these next-generation cancer treatments.

The details

Through the partnership, uBriGene will leverage its proprietary LVV Turbo™ platform, which integrates high-productivity cell lines, closed downstream purification, and enhancer technologies to deliver higher yield, higher potency, and lower cost lentiviral vectors. This will support the clinical development and future scalability of Cellinfinity's in vivo CAR-T programs targeting solid tumors and hematologic malignancies.

  • The strategic partnership was announced on March 30, 2026.

The players

uBriGene Biosciences

A leading global CDMO specializing in lentiviral vector manufacturing and advanced therapy medicinal product development.

Cellinfinity BIO

A biotechnology company developing in vivo CAR-T therapies targeting hematologic and solid tumors.

Dr. Sun Xiulian

Co-founder and CTO of uBriGene.

Dr. Chen Sidi

Founder of Cellinfinity BIO.

Got photos? Submit your photos here. ›

What they’re saying

“We are excited about this strategic partnership with Cellinfinity BIO. In vivo CAR-T technologies have the potential to significantly reduce treatment costs.”

— Dr. Sun Xiulian, Co-founder and CTO of uBriGene

“uBriGene brings extensive expertise in plasmid and viral vector manufacturing, along with strong global regulatory capabilities. We are particularly impressed by their proprietary LVV Turbo™ platform and integrated CDMO capabilities.”

— Dr. Chen Sidi, Founder of Cellinfinity BIO

What’s next

The partnership will accelerate the clinical advancement of Cellinfinity BIO's therapeutic programs CIB-301 and CIB-350, with uBriGene providing GMP lentiviral vector manufacturing support.

The takeaway

This strategic collaboration leverages uBriGene's expertise in viral vector production and Cellinfinity's innovative in vivo CAR-T technologies, aiming to lower the cost of next-generation cancer treatments and improve patient access to these potentially transformative therapies.